surmount-1 trial tirzepatide non-diabetic obesity weight loss SURMOUNT-5: Bests Semaglutide in Head-to-Head Semaglutide vs. Tirzepatide for Obesity

Plozasiran Now Available in China: A Once-Every-3-Month siRNA Therapy for Familial Chylomicronemia Syndrome (FCS) Plozasiran now available in China marks a milestone for FCS patients, offering a new APOC3-targeted siRNA therapy to help lower triglyceride (TG) levels in adults Ciprocopan Approved in China as the Worlds First Once-Daily Oral CFB Inhibitor for PNH Ciprocopan approved in China as the worlds first once-daily oral Complement Factor B (CFB) inhibitor, bringing a new oral treatment option for patients with paroxysmal Oveporexton Approved First in China: The First OX2R Agonist Targeting the Underlying Mechanism of Type 1 Narcolepsy Oveporexton approved first in China, becoming the worlds first approved selective orexin receptor 2 (OX2R) agonist and the first therapy designed to target the underlying Gene Therapy for Beta Thalassemia: Can CRISPR and Gene Addition Achieve Transfusion Independence

doi:10.1016/j.neuropharm.2013.08.005 142

J Am Pharm Assoc

Studies suggest that people with CFS usually have significantly lower glutathione levels, contributing to fatigue and weakened immunity